한국어
Quantus

EyeGene

185490 · KOSDAQ
₩1,990+2.58%
2026-09-04 close

EyeGene last closed at ₩1,990 (+2.58%) on 2026-09-04. Signals today: MA aligned. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
CloseMA20MA60MA120
Super Strong RS 86 · top 14%

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Signal history

DateSignal+20 trading days

A record, not a prediction.

How this is calculated

"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

C+
Overall: 건강관리 201/291 · top 69%
Factor composite · relative position in sector

PER — · PBR 1.71 — own-history percentile 34/100 · 69/100

Open self-history band
PER34/100
PBR69/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -3.47
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-3.47
Beneish M-Score
-1.31

Statistical manipulation-risk signal

Sloan accrual
0.07%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -363%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 37% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 269 of 287, share 0%.

269 / 2870%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6아이진0%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-395%
Interest coverage
-19x
Return on equity (ROE)
-24.1%

Operating margin −5pp

Operating loss
Interest coverageBase -19x adverse case -19.2x
Return on equity (ROE)Base -24.1% adverse case -28.1%

Revenue −15%

Interest coverage risk
Interest coverageBase -19x adverse case -16.1x
Return on equity (ROE)Base -24.1% adverse case -23.8%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -19x adverse case -13.3x
Return on equity (ROE)Base -24.1% adverse case -28.3%

Interest coverage limit

Already below the limit by 415.8pp

Interest coverage limit at an operating margin of 20.8%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-19

Suppliers disclosed by the company in its 2026-03-19 annual report.

Suppliers without disclosed amount

유바이오로직스에한국비엠아이에CMOMCV

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 한국비엠아이29.94%2026-05-15 · 증감 +0.14%p

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

Recent filings

EyeGene's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About EyeGene
What technical signals does EyeGene (185490) have?
EyeGene current technical signals: MA alignment (score 0.79).
Is EyeGene a cup-and-handle pattern?
No. EyeGene has no valid cup-and-handle signal right now.
What are EyeGene's financials and valuation?
EyeGene's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy